资讯

MyChesCo on MSN17 小时
Aclaris Therapeutics Launches Phase 2 Trial for Promising Atopic Dermatitis Treatment
WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has announced the initiation of a Phase 2 trial for its investigational drug bosakitug (ATI-045), targeting moderate-to-severe atopic dermatitis ...